Russia's Federal Medical-Biological Agency has received a patent for the drug Leitragin.
According to Gadin.Net, this was reported by RIA Novosti.
Scientists from the FTBA's Scientific Center for Biomedical Technology have determined that the drug, originally called "dalargin", is actively involved in the healing and regeneration of tissues.
In addition, the substance in this class can play an active role in the organization of the immune response, reducing or repelling the effects of the "cytokine attack" - inflammatory substances, which leads to severe respiratory and general systemic disorders in patients with coronavirus infection.
It is noted that the drug is able to prevent or alleviate the complications of coronavirus.